Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SANN | Switzerland | CHF | Delayed | |
0QN1 | London | CHF | Real-time |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Thomas Meier | 60 | 2011 | Founder & Chairman |
Philipp Gutzwiller | 54 | 2017 | Non Executive Independent Director |
Bradley Carl Meyer | - | 2023 | Director |
Otto Schwarz | 68 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review